BioTech 365

FEBRUARY 25, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Super-resolution RNA imaging in live cells.Ribonucleic acid (RNA) is key to various fundamental biological processes. It transfers genetic information, translates it into proteins or supports gene regulation.

RNA 40

RNA Genetics Protein Gene 40

XTalks

JANUARY 21, 2025

The tricuspid valve, one of the heart’s four valves, regulates blood flow from the right atrium to the right ventricle, preventing backflow between these chambers. There, plasma is separated, and tumor DNA is identified by detecting genetic mutations, methylation patterns and fragmentation signals.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

Roots Analysis

OCTOBER 30, 2023

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.

RNA 40

RNA Vaccine Vaccination Development 40

Scienmag

APRIL 21, 2021

Suppressing a gene regulator could reduce pancreatic cancer resistance to vital chemotherapeutic treatment. Targeting an RNA to interrupt its activity could improve patient response to therapy and increase their overall survival. […].

RNA 70

RNA Gene Regulation Research 70

pharmaphorum

DECEMBER 1, 2020

Pfizer and BioNTech have filed their COVID-19 vaccine with the European medicines regulator, paving the way for a potential approval before the end of the year. The EMA has also confirmed it has received a filing from Moderna, which is producing a rival vaccine based on similar RNA technology.

Vaccine 88

Vaccine Vaccination RNA Clinical Trials 88

BioPharma Reporter

JULY 21, 2022

US biotech, CAMP4 Therapeutics, has secured US$100m in a Series B financing round that it says will be used to accelerate expansion of its regulatory RNA (regRNA) platform.

Genetic Disease 52

Genetic Disease RNA Genetics Regulation 52

Scienmag

FEBRUARY 3, 2021

Altered epigenetic marks on ribosomal RNAs appear to create a pool of specialized ribosomes that can differentially regulate translation of specific messenger RNA Credit: UAB BIRMINGHAM, Ala.

RNA 60

RNA Regulation Genetics Medicine 60

Scienmag

DECEMBER 22, 2020

Credit: Kung-Chi Chang/Spector lab, 2020 Cold Spring Harbor Laboratory (CSHL) scientists have discovered a gene-regulating snippet of RNA that may contribute to the spread of many breast cancers. The same strategy, […].

RNA 52

RNA Gene Scientist Regulation 52

The Pharma Data

JANUARY 19, 2021

In the paper, researchers from Johns Hopkins University and elsewhere found a natural long-form transactivating CRISPR RNA (tracr-L) in Streptococcus pyogenes that functions to downregulate its endogenous CRISPR-Cas9 system. But altering the tracr-L with genetic engineering to make it function more like a guide RNA increased CRISPR-Cas9 cuts.

Bacteria 52

Bacteria Gene Editing Research RNA 52

Scienmag

NOVEMBER 16, 2020

Singapore scientists uncover potential role of long non-coding RNAs in pancreatic cancer Credit: From Figure 4 in Liu, S., Wnt-regulated lncRNA discovery enhanced by in vivo identification and CRISPRi functional validation. Harmston, N., Glaser, T.L. Genome Med 12, 89 (2020).

In-Vivo 53

In-Vivo RNA DNA Genome 53

pharmaphorum

OCTOBER 6, 2020

The announcement comes just days after the regulator said its CHMP scientific committee had begun to look at the first batch of data from AZ’s rival. The vaccine is based on different technology from AZ’s rival: while AZ’s uses a weakened and genetically modified cold virus to prime the immune system, BNT162b2 is based on a string of RNA.

Vaccine 59

Vaccine Vaccination RNA Immune Response 59

XTalks

APRIL 6, 2022

XTALKS WEBINAR: Using CRISPR interference (CRISPRi) Viability Screens to Map Long Noncoding RNA Dependencies in Tumor Cells. Register for this webinar to get an overview of the role of long non-protein coding RNAs (lncRNAs) in gene regulations. Live and On-Demand: Thursday, April 21, 2022, at 11am EDT (4pm BST/UK).

DNA 105

DNA In-Vitro Doctors Doctor 105

pharmaphorum

NOVEMBER 18, 2021

The two companies have been working together since 2019 to develop multiple RNA interference (RNAi) candidates for disorders such as non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases. billion in cash.

Gene Silencing 52

Gene Silencing RNA Protein Gene 52

pharmaphorum

SEPTEMBER 21, 2020

A group of rare genetic disorders, FCS affects between 55 and 110 people in England and causes very high levels of triglyceride fat in the blood. The drug works by reducing the production of ApoC-III, a protein that regulates plasma triglycerides.

Drugs 80

Drugs RNA Medicine Genetics 80

pharmaphorum

NOVEMBER 24, 2020

The FDA has approved Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), an ultra-rare and life-threatening genetic disorder. Oxlumo (lumasiran) was also approved in the European Union last week, making it the third from Alnylam’s pipeline of RNA interference therapeutics to make it to market.

FDA Approval 52

FDA Approval Gene Silencing Drugs RNA 52

Pharmaceutical Technology

APRIL 24, 2023

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. Langer, now a David H. This intersection will be remembered as one of the most significant achievements in science and medicine”.

Drug Delivery 147

Drug Delivery Vaccination Vaccine Research 147

XTalks

JANUARY 3, 2025

FCS is a rare genetic disorder that prevents the body from properly breaking down triglycerides (a type of fat in the blood), leading to dangerously high levels. Tryngolza works by targeting a protein in the liver, apoC-III, which regulates triglyceride metabolism.

FDA Approval 59

FDA Approval Drugs Clinical Trials Clinical Trials 59

The Pharma Data

MARCH 23, 2022

Back in 2018, researchers tested a broad-spectrum antiviral candidate called remdesivir/VEKLURY, which acts as a nucleotide decoy to get incorporated into the viral RNA genome and stop viral polymerase. Early in infection, it appears that host cellular proteins are in defense mode against Ebola virus polymerase and the viral genetic material.

Protein 52

Protein Genomics Genome Research 52

Delveinsight

JANUARY 18, 2021

Angelman syndrome (AS) is a complex genetic rare disorder that affects the nervous system. For instance, GTX-102 , an antisense therapy silencing the gene expression by binding to the RNA molecule behind the regulation of its expression, has also secured USFDA Fast Track Designation.

Marketing 52

Marketing Gene Drugs Protein 52

The Pharma Data

MARCH 5, 2021

This will be adapted to the needs of messenger RNA vaccine production for CureVac’s CVnCoV, the manufacturing of which is highly complex. Production will take place in a new high-tech production facility that was already under construction at the Novartis Kundl, Austria site. Disclaimer.

Manufacturing 52

Manufacturing Vaccination Vaccine Production 52

The Pharma Data

NOVEMBER 4, 2020

Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today the opening of its walk-in COVID-19 testing facility at the newly opened Berlin Brandenburg Airport (BER). About CENTOGENE.

Genetics 40

Genetics In-Vitro Biobanking Containment 40

Pharmaceutical Technology

JUNE 4, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Transcription factors for genetically modified cells. However, not all innovations are equal and nor do they follow a constant upward trend.

Genetics 130

Genetics Gene Expression DNA Antibody 130

XTalks

AUGUST 30, 2022

Such therapies may involve small interfering RNA (siRNA) or oligonucleotides in viral transfection platforms, large molecules and antibodies. The return of cell therapy-iPSCs (induced pluripotent stem cells) and genetically altered delivery cells. Optimization of dose and distribution to specific targets. The patients are waiting!

Trials 83

Trials Drug Delivery Drugs Gene 83

XTalks

OCTOBER 8, 2024

The 2024 Nobel Prize in Physiology or Medicine has been awarded to American scientists Victor Ambros and Gary Ruvkun for their groundbreaking discovery of microRNA (or miRNA) and its role in post-transcriptional gene regulation. However, microRNAs can bind to this mRNA, preventing it from functioning.

Regulation 52

Regulation Genetics Scientist RNA 52

Roots Analysis

OCTOBER 22, 2023

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. Non-coding RNAs include antisense oligonucleotides (ASOs) and RNA aptamers.

RNA 40

RNA Protein Genetics Gene Expression 40

pharmaphorum

NOVEMBER 9, 2020

Results will be discussed with regulators worldwide and the European Medicines Agency has already begun its rolling review of data to hasten a decision on the clinical trial dossier. The independent data monitoring committee that conducted the interim analysis said that there had been no serious safety concerns identified.

Vaccination 98

Vaccination Vaccine Clinical Trials Clinical Trials 98

The Pharma Data

JANUARY 21, 2021

In the ATLAS study, CABENUVA met the primary endpoint for noninferiority (the proportion of participants with plasma HIV-1 RNA ?50 50 copies per milliliter [c/mL] at Week 48), with a comparable number of patients receiving either CABENUVA or their daily current antiretroviral regimen (CAR) having an HIV-1 RNA level ?50

FDA Approval 52

FDA Approval RNA Drugs Containment 52

XTalks

NOVEMBER 7, 2022

Dr. Bahassi explained that technological advances in genetic sequencing of cfDNA have enabled liquid biopsies and led to marked increase in the detection of therapeutically-targetable mutations. Also, exosomes are mostly being used for the detection of circulating RNA and microRNA. “An

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

XTalks

MAY 4, 2021

Researchers at the University of California San Francisco (UCSF) and the Whitehead Institute have developed a novel CRISPR-based tool called “CRISPRoff” that can switch off genes in human cells through epigenetic editing without altering the genetic sequence itself. Epigenetic Editing with CRISPR.

DNA 98

DNA Gene Gene Silencing Genome 98

Roots Analysis

AUGUST 31, 2023

It is worth noting that the transcription factor is responsible for recruiting RNA polymerase to bind to the gene and produce messenger RNA, which is then translated into the protein. An additional level of genetic control is provided by gene switches that are located upstream of the promoter region.

Gene 40

Gene Gene Therapy Gene Expression Regulation 40

XTalks

MAY 4, 2021

Researchers at the University of California San Francisco (UCSF) and the Whitehead Institute have developed a novel CRISPR-based tool called “CRISPRoff” that can switch off genes in human cells without editing the genetic sequence itself. These modifications regulate gene expression without altering the sequence or structure of DNA.

DNA 52

DNA Gene Gene Silencing Genome 52

The Pharma Data

SEPTEMBER 22, 2020

All patients deserve a gene therapy designed to address the genetic root cause of their disease with a single dose. The company’s commitment to SMA extends beyond gene therapy to branaplam (LMI070), an oral, once-weekly RNA splicing modulator also currently under development, to expand the treatment options for SMA patients. .

Clinical Development 52

Clinical Development Gene Therapy Development Gene 52

The Pharma Data

JANUARY 21, 2021

Public health and infectious disease experts will need to continue to track new variants of COVID and decipher their genetics, just in case a new mutation causes a severe decline in vaccine effectiveness, the experts said. “That process is done so efficiently by the [U.S. . “That process is done so efficiently by the [U.S.

Vaccination 52

Vaccination Vaccine Protein Immune Response 52

The Pharma Data

MARCH 4, 2021

Dravet syndrome is most commonly caused by a genetic mutation in the SCN1A gene and affects approximately 1 in 15,000 to 1 in 21,000 people in the United States. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI).

Development 52

Development Containment Medicine Clinical Trials 52

The Pharma Data

AUGUST 30, 2021

As the first and only small interfering RNA to provide effective and sustained LDL-C reduction, Leqvio helps manage a critical cardiovascular risk factor for ASCVD. Leqvio is the first and only approved small interfering RNA (siRNA) LDL-C-lowering treatment in Europe 6,7. It is currently under review by the U.S. a statin or ezetimibe).

RNA 52

RNA Trials Production Containment 52

The Pharma Data

DECEMBER 18, 2020

The Moderna COVID-19 Vaccine contains messenger RNA (mRNA), which is genetic material. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products. SOURCE U.S. Source link.

Vaccine 52

Vaccine Vaccination Production Manufacturing 52

Delveinsight

SEPTEMBER 23, 2021

858 Therapeutics closes USD 60 Million series A round to drug RNA modulation. Now, they are ready for their next venture, which is launching RNA biotech 858 Therapeutics with a USD 60 million Series A fundraising. 858’s drug candidates include proteins, which regulate RNA and immune response. Jeffrey Stafford, Ph.D.,

RNA 61

RNA Gene Therapy Gene Protein 61